1 / 1

PI Mauro D'Amato, Department of Biosciences and Nutrition

Post-genomic applications in IBD: exploitation of genetic information towards improved diagnosis and therapy. PI Mauro D'Amato, Department of Biosciences and Nutrition. Objectives Advance our understanding of inflammatory bowel disease pathogenesis by

paley
Télécharger la présentation

PI Mauro D'Amato, Department of Biosciences and Nutrition

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Post-genomic applications in IBD: exploitation of genetic information towards improved diagnosis and therapy PIMauro D'Amato, Department of Biosciences and Nutrition Objectives Advance our understanding of inflammatory bowel disease pathogenesis by • Studying expression profiles of all 170 known IBD risk genes and relevant pathways in different tissues from patients and controls (focus on IL23R, IL13, NOD2) • Correlating these profiles with genotype at all corresponding loci Establish disease diagnostic and predictive scores via computational integration of • Phenotype data (at recruitment and follow-up for patients) • Genotype data for all 170 known IBD risk loci • “Omics” profiles (RNA/protein expression) for all 170 known IBD risk loci Pave the way for personalized therapeutic approaches based on • Multilayer data integration (genotype, eQTL, GEX, drug targets and properties) for the identification of drug repositioning candidates or new compounds • In vitro and ex vivo preliminary validation of novel drug indications Clinical cohorts Swedish Interception Cohort for IBD ~1000 newly diagnosed, treatment naive patients followed for 10 years (recruitment ongoing) blood, serum and intestinal biopsies Technologies DNA/RNA/protein profiling, data integration and predictive modelling AZ contributions Jan Kilhamn (CVGI), Magnus Ivarsson (TSC)

More Related